Dendritic cells in cancer immunotherapy
Open Access
- 29 July 2010
- journal article
- viewpoints on-dc
- Published by Wiley in European Journal of Immunology
- Vol. 40 (8), 2123-2130
- https://doi.org/10.1002/eji.201040630
Abstract
DC initiate and regulate T-cell immunity and are thus the key to optimization of all types of vaccines. Insights into DC biology offer many opportunities to enhance immunogenicity. In this Viewpoint, I discuss some recent developments and findings that are of immediate relevance for the clinical development of cancer vaccines. In addition, I emphasize my personal view that we should explore the potential of adoptively transferred DC (i.e. DC vaccination) as cancer vaccines by performing two-armed trials that address critical variables and by delivering antigens via mRNA-transfected DC.Keywords
This publication has 101 references indexed in Scilit:
- Dendritic cells in tolerance induction for the treatment of autoimmune diseasesEuropean Journal of Immunology, 2010
- Polarized dendritic cells as cancer vaccines: Directing effector-type T cells to tumorsSeminars in Immunology, 2010
- Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapyClinical Immunology, 2010
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010
- A comprehensive catalogue of somatic mutations from a human cancer genomeNature, 2009
- Use of tumour-responsive T cells as cancer treatmentThe Lancet, 2009
- Natural killer cell–directed therapies: moving from unexpected results to successful strategiesNature Immunology, 2008
- Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migrationCancer Immunology, Immunotherapy, 2008
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patientsProceedings of the National Academy of Sciences, 2008
- Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on primingProceedings of the National Academy of Sciences, 2008